SeaCrest Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

SeaCrest Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3	Closed	-$1K	–	783
2019 Q1	$1K	Hold	3	–	–	﹤0.01%	2000
2018 Q4	$1K	Hold	3	–	–	﹤0.01%	1989
2018 Q3	$1K	Buy	+3	New	+$485	﹤0.01%	2140

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SeaCrest Wealth Management's CRBP Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2019, closing a stake of 3 shares — an estimated $1K sold.

SeaCrest Wealth Management first reported a position in CRBP in Q3 2018 and held it in 3 quarters. The position peaked at $1K in Q1 2019. 103 funds tracked by Wall St. Rank hold CRBP as of Q2 2019.

SeaCrest Wealth Management reported no remaining Corbus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 3 Corbus Pharmaceuticals shares in Q2 2019, an estimated $1K.
SeaCrest Wealth Management first reported a position in Corbus Pharmaceuticals in Q3 2018 and held it in 3 quarters.
SeaCrest Wealth Management's Corbus Pharmaceuticals position peaked at $1K in Q1 2019.
103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.